Samtheo Biopharma Forms Subsidiary Lyndor Bioscience to Develop Moffitt Cancer Center Rx

Samtheo formed Lyndor to further develop a small molecule licensed from Moffitt to treat chemo- and radiation-resistant cancer patients. Lyndor and Moffitt will continue to co-develop the treatment with the hopes of signing on a larger pharmaceutical partner.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.